Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Genetics and Molecular Pathology, |
RCV002466911 | SCV002761812 | uncertain significance | Autosomal dominant hypocalcemia 1 | 2022-04-08 | criteria provided, single submitter | clinical testing | |
Athena Diagnostics | RCV002473388 | SCV002771683 | uncertain significance | not provided | 2021-07-22 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV003775493 | SCV004578725 | uncertain significance | Familial hypocalciuric hypercalcemia; Autosomal dominant hypocalcemia 1 | 2022-11-20 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive. This variant has not been reported in the literature in individuals affected with CASR-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces glycine, which is neutral and non-polar, with aspartic acid, which is acidic and polar, at codon 685 of the CASR protein (p.Gly685Asp). |